TacticScaleWhat STAAR Surgical Does & How It Makes Money (STAA)
Updated October 2026 · reflects STAAR Surgical's latest reported financials
Maker of implantable contact-style lenses that correct vision. It earns revenue by selling its ICL lenses and delivery systems to eye surgeons, surgical centers, hospitals and distributors, using direct sales teams in markets like Japan, the U.S.
How STAAR Surgical makes money
It earns revenue by selling its ICL lenses and delivery systems to eye surgeons, surgical centers, hospitals and distributors, using direct sales teams in markets like Japan, the U.S. and Germany and independent distributors in China, Korea, India and elsewhere.
What STAAR Surgical does
STAAR Surgical, founded in 1982 and headquartered in Lake Forest, California, specializes in phakic implantable lenses — lenses placed inside the eye alongside the eye's natural lens to correct refractive errors. Its core Implantable Collamer Lens (ICL) family, including EVO, EVO+, EVO Visian and EVO Viva, targets myopia, hyperopia, astigmatism and presbyopia, positioning it as an alternative to laser-based refractive surgery. The company sells to ophthalmic surgeons, vision and surgical centers, hospitals and government facilities. It relies on direct sales in Japan, the U.S., Germany, Spain, Singapore, Canada and the U.K., and on independent distributors in China, Korea, India, France, Benelux, Italy and other international markets, so a large share of its business is outside the U.S.
Products & services
- EVO ICL
- EVO+ ICL
- EVO Visian ICL
- EVO Viva ICL
- ICL delivery systems
What is STAAR Surgical worth?
On an owner-earnings DCF, STAAR Surgical's most-likely value is about $12 versus a recent price near $22 (43% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$4) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
The Cooper Companies (COO) · Glaukos (GKOS) · STERIS (STE) · Eyebright Medical Technology (Beijing) (688050.SS) · Autek China (300595.SZ)